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Abstract
Background: Adenocarcinoma of the pancreas is one of the most aggressive tumor diseases affecting the human
body. The oncogenic potential of pancreatic cancer is mainly characterized by extremely rapid growth triggered by
the activation of oncogenic signaling cascades, which suggests a change in the regulation of important
transcription factors. Amongst others, NFAT transcription factors are assumed to play a central role in the
carcinogenesis of pancreatic cancer. Recent research has shown the importance of the transcription factor Sp1 in
the transcriptional activity of NFATc2 in pancreatic cancer. However, the role of the interaction between these two
binding partners remains unclear. The current study investigated the role of Sp1 proteins in the expression of
NFATc2 target genes and identified new target genes and their function in cells. A further objective was the
domain of the Sp1 protein that mediates interaction with NFATc2.
The involvement of Sp1 proteins in NFATc2 target genes was shown by means of a gene expression profile
analysis, and the results were confirmed by quantitative RT-PCR. The functional impact of this interaction was
shown in a thymidine incorporation assay. A second objective was the physical interaction between NFATc2 and
different Sp1 deletion mutants that was investigated by means of immunoprecipitation.
Results: In pancreatic cancer, the proto-oncogene c-Fos, the tumor necrosis factor TNF-alpha, and the adhesion
molecule integrin beta-3 are target genes of the interaction between Sp1 and NFATc2. Loss of just one
transcription factor inhibits oncogenic complex formation and expression of cell cycle-regulating genes, thus
verifiably decreasing the carcinogenic effect. The current study also showed the interaction between the
transcription factor NFATc2 and the N-terminal domain of Sp1 in pancreatic cancer cells. Sp1 increases the activity
of NFATc2 in the NFAT-responsive promoter.
Conclusions: The regulation of gene promotors during transcription is a rather complex process because of the
involvement of many proteins that – as transcription factors or co-factors – regulate promotor activity as required
and control cell function. NFATc2 and Sp1 seem to play a key role in the progression of pancreatic cancer.
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Background
Malignant tumor diseases are one of the major causes of
death worldwide [1]. One tumor disease with a very low
survival rate is adenocarcinoma of the pancreas [2]. Be-
cause of the lack of characteristic early symptoms and
effective screening tests, most tumors are classified as
incurable cancer with a poor prognosis at the time of
diagnosis [3]. Thus, current research is focused on the
development of alternative treatment methods that aim
at the efficient modulation of specific signaling and tran-
scription pathways [4]. The prerequisite for developing
new therapeutic approaches to ‚targeted therapies’ is de-
tailed knowledge on the carcinogenesis of pancreatic
cancer [5].
The pathogenesis of pancreatic cancer shows charac-
teristic changes in morphology that are associated with
typical genetic alterations [6]. On the basis of this know-
ledge, a tumor progression model was developed
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describing the gradual process of pancreatic cancer from
its neoplastic preliminary stage – termed PanIN (pancre-
atic intraepithal neoplasia) – to its malignant stage [7].
This process not only involves various mutations but
also genetic changes such as oncogene mutations,
changes in tumor suppressor genes, as well as
over-expression of growth factors and their receptors
[8]. This series of mutations upsets the balance between
tumor-suppressing and tumor-promoting pathways.
The carcinogenesis of pancreatic cancer is character-
ized by the modified activation of signaling pathways
and the changed regulation of important transcription
factors [9], particularly of the family of NFAT transcrip-
tion factors [10]. Buchholz et al. have shown the increas-
ing synthesization of both NFATc1 and NFATc2 in the
preliminary stages of pancreatic carcinoma [11]. Further-
more, immunohistochemically examined pancreatic
tumor cells have shown expression of NFAT in 91.7% of
cases. In more than 80% of pancreatic tumor tissue, such
over-expression is caused by the amplification of
NFATc2 on the chromosome 20q13 [12].
In pancreatic cancer, the oncogenic transcription fac-
tor Sp1 (specificity protein 1) plays a central role in the
transcriptional and functional activity of NFATc2. Sp1
belongs to the family of zinc finger proteins. Sp1 is com-
posed of an N-terminus consisting of activating domains
that weight about 70 kDa as well as of 3 zinc fingers
measuring about 15 kDa that are localized at the
C-terminal part. The 3 zinc fingers simultaneously rep-
resent the DNA-binding domain [13]. The correspond-
ing complex formation between Sp1 and its binding
partners occurs at the intracellular level [14]. Santini et
al. already described the interaction between NFATc2
and Sp1 in keratinocytes in 2001 [15]. This interaction
could be confirmed by our research team for pancreatic
cancer cells, in which transcription factors of the same
immune complex directly interact at the NFAT-DNA
target sequence GGAAA and also have a joint function
[14]. However, the role of this interaction in pancreatic
cancer is still unclear.
The current study investigated the role of Sp1 proteins in
the expression of NFATc2 target genes and identified new
target genes and their function in cells. Thus, a selective
and therefore specific blockade of this oncogenic complex
formation in the sense of ‘targeted therapy’ seems possible
at a translational level. The domain of the Sp1 protein in
which the interaction with NFATc2 takes place is of vital
importance in this context to avoid disturbance of the
physiological function of NFATc2 and Sp1 in the organism.
Methods
Chemicals, reagents, equipment an methodology
used in the current study were mostly described pre-
viously in [13].
Cell lines
The human pancreatic adenocarcinoma cell lines PaTu
8988 t were obtained from H. P. Elsässer (Philipps Univer-
sity of Marburg, Germany). PaTu 8988 t cells were
maintained in Dulbecco’s modified Eagle’s medium (Sig-
ma-Aldrich) supplemented with 10% fetal calf serum (Sig-
ma-Aldrich) and 1% Normocyn (Fa. Amaxa biosystems).
Cells were cultured at 37 °C in humidified CO2 atmosphere
(5%) and maintained in monolayer culture. Experiments
were done with cells at ~ 70–80% confluence.
Reagents, siRNA transfection, and transient transfection
Ionomycin was purchased from Sigma-Aldrich. For
siRNA transfection, NFATc2 siRNA (5`-CCAUUAAAC
AGGAGCAGAAtt-3`), Sp1 siRNA (5`-GGUAGCUCU
AAGUUUUGAUtt-3`) and the Silencer Negative Con-
trol were obtained from Ambion (Applied Biosystems).
Cells were transfected with the siLentFect lipid reagent
(Biorad) for 24 h according to the manufacturer’s
protocol.
For the transient transfection of expression constructs,
PaTu 8988 t cells were transfected 24 h after seeding at
70% density, using TransFast (Promega) as a transfection
reagent according to the manufacturer’s instructions.
The Sp1 ZF- flag and Sp1 N-term-flag expression con-
structs were kindly provided by Dr. J. S. Zhang (Mayo
Clinic, Minnesota, USA), mNFATc2-HA by Dr. A. Rao
(Harvard Medical School, Boston, USA), and the pro-
moter constructs cisNFAT-Luc by Stratagene Garden
Grove.
Quantitative real-time polymerase chain reaction analysis
and gene expression analysis
RNA was extracted using the RNeasy Mini Kit (Qiagen).
First-strand complementary DNA was synthesized using
a First Strand cDNA Synthesis Kit (SuperArray Bio-
science Corporation). Quantitative reverse transcription
-polymerase chain reaction (RT-PCR) analysis was done
with 7500 Fast Real-time PCR and the SYBR Green PCR
Master Mix Kit (Applied Biosystems) according to the
manufacturer’s instructions. RPLP0 was used as a house-
keeping gene for normalizing gene expression. Primers
with the following sequences were used for expression
analysis: cFos (forward: 5`-AGTCCTTACCTCTT
CCGGAGATG-3`; reverse: 5`-GCCTGGCTCAACAT
GCTAC TAA-3`). All primers had been obtained from
Biomers.
For analysis of gene expression according to the man-
ufacturer’s instructions. Extracted mRNA is transcribed
into cDNA and mixed with the ‘SuperArray SYBR Green
Mastermix’ containing oligonucleotide primers followed
by quantitative Real-Time-PCR analysis and evaluation
by means of the ΔΔCT method. All primers had been
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obtained from Qiagen. The gene using listed in
Additional file 1: Table S1.
Subcellular fractionation, co-immunoprecipitation, and
immunoblotting
For subcellular fractionation, cells were washed twice
with cold DPBS and resuspended in lysis buffer (12.5 mL
1M HEPES, ph 7.5, 7.5 mL 5M NaCl, 1.25 mL 200mM
EGTA, 25 mL 100% Gycerin, 2.5 mL Triton X-100, 1.05 g
NaF, 1.11 g Na4P2O7 × 10 H2O) containing protease in-
hibitors. After sonification, cells were centrifuged at
13.000 rpm for 5 min, and supernatants were transferred
to new cups and incubated on ice.
For co-immunoprecipitation, 500 μg of lysates was
immunoprecipitated with 4 μL of the indicated antibodies
and protein G or A agarose (Roche Diagnostics). The im-
munoprecipitates were subjected to immunoblotting.
For Western blotting, protein extracts were analyzed
by SDS-PAGE and blotted onto nitrocellulose. Upon
protein extraction and gel transfer, membranes were
washed in TBS washing buffer and incubated with
peroxidase-conjugated secondary antibodies. Immunore-
active proteins were visualized by means of an enhanced
chemiluminescence detection system (Western Blotting
Detection Reagent, GE Healthcare). Membranes were
probed with NFATc2 (Santa Cruz Biotechnology) and
Anti-FLAG (Sigma-Aldrich) antibodies.
Luciferase reporter assay
Cells were seeded onto 12 well plates; after 24 h, cells
were either transfected with the indicated constructs or
treated. Luciferase activity was measured with the Lumat
LB 9501 (Berthold Technologies) luminometer and the
dual Luciferase Reporter Assay System (Promega) ac-
cording to the manufacturer’s instructions. Firefly lucif-
erase values were normalized to Renilla luciferase
activity and are shown as mean values ±SD.
Proliferation assays
Cells were seeded onto 24 well plates and cultured in
medium containing 10% FCS. 19 h after the indicated
treatment with siRNA or transfection, [3H]thymidine
(0.5 μCi/well) was added during the last 5 h of incubation.
The cells were washed with 5% trichloroacetic acid, and
the acid-insoluble fraction was dissolved using incubation
in 1mol/L NaOH at 37 °C for 30min. Radioactivity was
evaluated with a scintillation counter (Pharmacia).
Statistical analysis
Data are presented as mean ± SD. The t-test was used
for statistical evaluation of the data. P values of < 0.05
were considered statistically significant.
Results
Involve of Sp1 on gene transcription mediated by NFATc2
An expression profile of PaTu 8988 t cells was created to
investigate the role of Sp1 proteins in the expression
of NFATc2 target genes and to identify new target
genes. A prerequisite for achieving this aim is the re-
liable translocation of NFATc2 into the cell nucleus
by means of a stimulus. A suitable stimulant in this
respect is Ionomycin that initiates the influx of cal-
cium into the cell, which subsequently activates the
calcium-calcineurin-NFAT signaling pathway, depho-
sphorylizes NFAT, dislocates the cell nucleus, and in-
creases DNA affinity.
For this purpose, mRNA was extracted from various
pre-treated PaTu 8988 t lysates:
1) Untreated control,
2) Cells treated with Ionomycin 1 h previously,
3) Cells, in which Sp1 is repressed with RNA interfer-
ence, and
4) Cells, stimulated with siRNA for Sp1 and addition-
ally with Ionomycin for 1 h.
The lysates were assessed in the expression profile
analysis that contained 89 different genes involved in the
carcinogenesis of pancreatic cancer. Expression was
measured with the 7500 fast real time PCR system.
The genes used for this purpose mainly stemmed
from the following areas: cell cycle, transcription, sig-
nal transduction, and extracellular matrix. For analysis
of gene expression the gene using listed in Additional
file 1: Table S1. After the administration of Ionomy-
cin, altogether 11 genes were expressed, for instance
the proto-oncogene c-Fos and the tumor necrosis
factor TNF-alpha that were both up-regulated (Fig. 1a
+ b). The results showed reduced synthesization of
the molecules APAF1, ATM, BCL2, BRCA1, and
TNFRSF25 involved in apoptosis, of the adhesion
molecules integrin alpha-2 and integrin beta-3, of the
metastasis suppressor gene MTSS1, as well as of
phosphoinositide-3-kinase PI3K (Fig. 1c-k).
It was remarkable that Sp1 inhibition minimized the
effect of Ionomycin on c-Fos and TNF-alpha, whereas
the administration of Ionomycin increased expression
in the control group (band 2 in each case). Repres-
sion of Sp1 with RNAi technology significantly influ-
enced the effect of Ionomycin by Sp1 inhibition
(band 4 in each case). NFATc2 and Sp1 also had an
antagonizing effect on ITGB3. Stimulation of control
cells with Ionomycin decreased mRNA expression.
The same effect could be achieved by inhibiting Sp1
with RNAi technology. However, treatment of cells
with a combination of siSp1 and Ionomycin decreased
mRNA expression by further 25% (Fig. 1h). According
to our results, Sp1 only plays a tangential role in
regulating NFATc2 in the 8 remaining genes.
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Fig. 1 (See legend on next page.)
Malsy et al. BMC Biochemistry            (2019) 20:2 Page 4 of 11
Quantitative RT-PCR for confirming the expression profile
To confirm the result of the expression profile analysis,
we independently analyzed the mRNA level of c-Fos by
means of quantitative RT-PCR (Fig. 2). In this analysis,
the activity of c-Fos in an untreated control group was
normalized to the value of 100, and the influence of the
regulatory change is shown as the x-fold increase or de-
crease of this control. The untreated control group
showed significantly (4.5-fold) increased expression of
c-Fos after the administration of Ionomycin (band 2).
Repression of Sp1 with RNAi significantly influenced the
effect of Ionomycin by Sp1 inhibition (band 4).
Knock-down of the interaction partners NFATc2 and Sp1
with RNAi technology reduced cell proliferation
The impact of the interaction between NFATc2 and Sp1
on cell proliferation was investigated by means of a thy-
midine incorporation assay (Fig. 3). For this purpose,
pancreatic cancer cells were transiently transfected with
‘Silencer Negative Control’-siRNA or a silencer-RNA se-
quence for NFATc2 or Sp1, or both. Proliferation was
measured by means of radioactive thymidine incorpor-
ation into the cell in the beta counter. The activity of an
untreated control group was normalized to the value of
100, and the influence of the regulatory change is shown
as the x-fold increase or decrease of this control.
Basal proliferative activity of the cell was visible in
band 1. Transfection of siNFATc2 (band 2) reduced pro-
liferation to 71% after 24 h (Fig. 3a) and to 67% after 48
h (Fig. 3b), whereas transfection of siSp1 decreased pro-
liferation to 49% (Fig. 3a) and 70% respectively (Fig. 3b).
Inhibition of both transcription factors by siRNA
knock-down (band 4) yielded a further but insignificant
reduction in cell proliferation to 43% after 24 h and 53%
after 48 h. Fig. 3c shows the knockdown efficiency of the
siRNA used.
Physical interaction between NFATc2 and the deletion
mutant Sp1 N-terminus
Immunoprecipitation tests were conducted to investigate
which domain of the Sp1 protein mediates interaction
with NFATc2. For this purpose, the pancreatic cancer
cell line PaTu 8988 t was transiently transfected with the
effector plasmids of the Sp1 deletion mutants FLAG Sp1
C-terminus (zinc finger domain) and FLAG Sp1
N-terminus. NFATc2 was precipitated with agarose and
NFATc2 antibodies and evaluated by means of Western
blot analysis (Fig. 4a). The two bands of NFATc2 show
the different stages of phosphorylization of the protein.
Co-immunoprecipitated Sp1 deletion mutants were
shown using anti-FLAG antibodies (Fig. 4b). The signal
(See figure on previous page.)
Fig. 1 a - k: Expression profile analysis depending on the treatment with Ionomycin. Four different groups of mRNA are produced from PaTu
8988t lysates: 1) Untreated control lysates, 2) Lysates from cells treated with Ionomycin 1 h previously, 3) Cell lysates in which Sp1 is repressed
with RNA interference, and 4) Lysates stimulated with siRNA for Sp1 and additionally with Ionomycin for 1 h. The lysates were assessed in the
expression profile analysis that contained 89 different genes involved in the carcinogenesis of pancreatic cancer. After the administration of
Ionomycin, altogether 11 genes (Fig. 1a - k) were expressed. The basal activity of the genes in the control lysate is normalized to the value of
100, and the influence of the regulatory change is shown as the x-fold increase or decrease of this control. Data are presented as mean ± SD.
The t-test was used for statistical evaluation of the data. P values of <0.05 were considered statistically significant
Fig. 2 Quantitative Real Time-PCR analysis of 8988 t cells of c-Fos. PaTu 8988 t cells are divided into four groups followed by isolation of their
mRNA. 1) Untreated control, 2) Cells treated with Ionomycin 1 h previously, 3) Cells, in which Sp1 is repressed with RNA interference, and 4) Cells,
stimulated with siRNA for Sp1 and additionally with Ionomycin for 1 h. The relative mRNA expression of c-Fos is determined by means of qRT-
PCR. Data are presented as mean ± SD. The t-test was used for statistical evaluation of the data. P values of < 0.05 were considered
statistically significant
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for Sp1 N-terminus was rather strong, but no signal
could be detected for Sp1 C-terminus.
Functional interaction between NFATc2 and Sp1 N-
terminus in the dual luciferase assay
After having shown the physical interaction between
NFATc2 and Sp1 N-terminus in immunoprecipitation
tests, we investigated their functional interaction by
means of the dual luciferase assay (Fig. 5). After transi-
ent transfection of the artificial NFAT-responsive
reporter-promotor-construct cisNFAT Luc as well as the
effector plasmids NFATc2, Sp1 C-terminus, and Sp1
N-terminus into the cell, the emitting light was quanti-
fied with a luminometer. Basal activity of the promotor
constructs cisNFAT Luc was normalized to a value of
100 followed by the assessment of the influence of the
regulatory change.
Band 1 shows the basic basal activity of the promotors,
whose effectiveness may be 10-fold increased by the
transcription factor NFATc2 (band 2). Cell transfection
only with Sp1 C-terminus or Sp1 N-terminus but not
NFATc2 did not or just very slightly increase light emis-
sion (band 3 and 5). Co-transfection of both interaction
partners only yielded a slight increase in band 4, but
Fig. 3 a, b, and c: Influence of NFATc2 and Sp1 on cell proliferation. PaTu 8988 t cells are transiently transfected with control-siRNA, siNFATc2,
and/or siSp1 and stimulated with serum for 24 h (Fig. 3a) or 48 h (Fig. 3b). Fig. 3c shows the knockdown efficiency of the used siRNA
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doubled light emission or promotor activity in band 6 in
comparison to the sole transfection of NFATc2.
In summary, immunoprecipitation tests could confirm
the physical interaction between NFATc2 and Sp1
N-terminus at the functional level.
Discussion
Binding partners are a decisive factor in the specificity of
transcription factors in cells. Recent investigations have
shown the important role of the oncogenic transcription
factor Sp1 in the transcriptional activity of NFATc2 in
pancreatic cancer [13], in which interaction between
binding partners occurs within the cell. However, the
role of this interaction in pancreatic cancer is still un-
clear. In the current study, several target genes of
NFATc2 were identified by means of expression profile
analysis, such as the proto-oncogene c-Fos, the tumor
necrosis factor TNF-alpha, the molecules APAF1, ATM,
BCL2, BRCA1 and TNFRSF25 involved in apoptosis, the
adhesion molecules integrin alpha-2 and integrin beta-3,
the metastasis suppressor gene MTSS1, as well as
phosphoinositide-3-kinase PI3K.
The tumor necrosis factor TNF-alpha takes a pivotal
position amongst cytokines. TNF-alpha is a pleiotropic
cytokine with a wide range of predominantly proinflam-
matory effects [16]. An anti-tumor effect has been ob-
served in patients with carcinoma who developed an
infectious disease, and this effect lasted over the entire
course of the infectious disease until remission [17]. Fur-
thermore, deregulated expression of TNF-alpha in the
Fig. 4 a and b: NFATc2 interacts with the N-terminus of Sp1. The deletion mutants FLAG-Sp1 C-terminus and FLAG-Sp1- N-terminus are over-
expressed into the cell. NFATc2 proteins are immunoprecipitated via an antibody and Sp1 binding to NFATc2 is shown in Western blot analysis
by means of an anti-FLAG antibody
Fig. 5 Functional interaction between NFATc2 and Sp1 in the dual luciferase assay. Dual luciferase assay by using the artificial NFAT-responsive
reporter-promotor construct cisNFAT-Luc and the effector plasmids NFATc2, Sp1-CT, and Sp1-NT. Cells are harvested after 24 h, and promoter
activation is determined by measuring light emission. Data are presented as mean ± SD. The t-test was used for statistical evaluation of the data.
P values of < 0.05 were considered statistically significant
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micro-environment of a tumor seems to promote tu-
moral invasion and migration and subsequently metasta-
sis [18]. In experimental animal studies, treatment of
ductal adenocarcinoma with TNF-alpha significantly
facilitated tumor growth and metastasis [19], whereas
treatment with infliximab and etanercept reduced
tumor growth, for instance of liver metastases [20].
NFAT-dependent TNF-alpha expression in lymphocytes
has already been described in the literature [21]. In this
study, this regulation could also been shown in pancre-
atic cancer cells. Because Sp1 inhibition remarkably re-
duces the effect of Ionomycin, the DNA-binding activity
of Sp1 also seems to play a role in NFATc2-mediated
regulation.
Sp1 dependence may also be observed in c-Fos, a pro-
tein belonging to the bHLH-Zip protein family. C-Fos
was first described by Finkel et al. in the 1970s, who
managed to isolate retroviruses from bone tumors.
The actual transforming insert has been termed
Fos-oncogene [22]. In the following years, the cellular
equivalent c-Fos was described for various types of tu-
mors, and the protein involved in neoplastic transform-
ation could be identified [23]. Transgenic mice that
over-express this molecule develop osteosarcoma and
chondrosarcoma. C-Fos causes high over-expression of
cyclin D1 in osteoblasts and chondrocytes, and this
over-expression results in the uncontrolled multiplica-
tion of cells [24]. Previous studies have found increased
mRNA and protein expression of c-Fos in the majority
of pancreatic cancer cells [25, 26]. Such induction has
also been described for other types of tumors in which
expression of c-Fos results in neoplastic transformation
[23]. Saez et al. have shown the important role of c-Fos
in the progression of malignant skin tumors [27]. Immu-
nohistochemical examinations and in-situ hybridization
studies have described the over-expression of c-Fos in
esophagus carcinoma. The transcription factor c-Fos has
been found in 66% of dysplasia and in 53% of squamous
cell carcinoma but only in less than 5% of normal
esophageal cellular tissue [28]. In contrast to c-Fos and
TNF-alpha in which the effects of Ionomycin and Sp1
are pooled, the adhesion molecule ITGB3 has an antag-
onizing effect on mRNA expression and is suppressed by
NFATc2 during treatment with Ionomycin.
Integrins are transmembrane, heterodimeric glyco-
proteins that consist of an alpha subunit and a beta
subunit. These glycoproteins bind to various proteins
of the extracellular matrix and mediate bidirectional
signal transduction [29]. Integrins can be differenti-
ated into 25 different subunits: 18 alpha and 8 beta
subunits [30]. The occurrence of integrins is usually
limited in time and restricted to the surface of cell
membranes. The presence or absence of integrins has
a strong impact on the growth, local invasion,
destruction, and metastasis of malignant tumors [31].
The NFAT-dependent regulation of integrins was
already described by Jauliac et al. in 2002 [32]. Be-
cause of the bipolar behavior of Sp1 that has already
been described several times in the literature [33],
NFATc2 und Sp1 may be assumed to mutually regu-
late the expression of ITGB3. Here, Sp1 acts as a
transcriptional repressor of NFATcs2 in the respective
GC box of the promoter.
In summary, data obtained from the expression profile
analysis and the qRT-PCR examinations in the current
study showed Sp1-dependent regulation of the pro-
moters of c-Fos, TNF-alpha, and ITGB3. The effect of
this regulation on pancreatic cancer cells was deter-
mined by means of a thymidine incorporation assay. Sole
repression of the transcription factors resulted in a de-
crease by about 40–50%, and this percentage was only
insignificantly diminished by mutual inhibition. One
possible interpretation is that the binding partners
NFATc2 and Sp1 interact and mutually regulate target
genes dependent on cellular growth. Loss of just one
transcription factor impedes oncogenic complex forma-
tion and expression of cell cycle-regulating genes. There-
fore, one possible therapeutic approach would be
inhibiting such interaction in the sense of ‘targeted ther-
apy’ in pancreatic cancer cells. Modern therapeutic ap-
proaches already target efficient modulations of specific
signaling and transcription pathways of individual fac-
tors [4]. This way, calcineurin-induced activation of
NFAT may be inhibited by administrating the immuno-
suppressant Cyclosporin A that irreversibly binds to the
catalytic domain of calcineurin, thus consecutively inhi-
biting the dephosphorylization of NFAT [34]. A further
example is the peptide VIVIT that disrupts the inter-
action between calcineurin and NFAT, thus blocking the
dephosphorylization of NFAT and impeding nuclear
translocation [35]. Tolfenaminic acid, a non-steroidal
anti-inflammatory drug, activates the degradation of
Sp1, Sp3, and Sp4 and reduces expression of the vascular
endothelial growth factor, hereby decreasing tumoral
growth and metastasis [36]. Furthermore, some drugs in-
hibit specific Sp1-dependent transactivation [37], for in-
stance oligonucleotides, peptide-nucleic acid, and DNA
chimaeras. Other drugs such as mithramycin disrupt the
binding of Sp-protein to the DNA [38], whereas agents
such as the Cox-2 inhibitor increase Sp-protein degrad-
ation [36].
At present, several inhibitors are being investigated in
the context of preclinical studies or have already been
established in clinical practice [39]. A possible new ap-
proach to treating pancreatic cancer is inhibiting the
interaction between NFATc2 and Sp1. As analyzed in
the current study, it is essential to know the domain of
the interaction between Sp1 and NFATc2 in the protein.
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All proteins of Sp-like transcription factors show simi-
lar structural domains: the C-terminus has three zinc
fingers, DNA-binding domains, a nuclear localization se-
quence (NLS), as well as a transcriptional-regulatory do-
main [40]. Zinc finger domains consist of 81 amino
acids of the Cys2His2 type [41]; here, 4 cysteines or histi-
dines act as ligands that form a zinc ion, so that the
amino acid chains are reciprocally arranged to one an-
other [42]. The N-terminus contains the activation do-
mains Sp1 to Sp4 from glutamine-rich regions adjacent
to serine-threonine-rich domains. Such threonine-rich
domains are post-translationally modified by glycosyla-
tion on several threonine residues [43] as well as by
phosphorylation and glycosylation on serine residues
[44]. These domains play a pivotal role in the regulation
of Sp1. Transcriptional activation is initiated in
glutamine-rich subsections as well as in the D-domain
(C-terminus), which has a synergistic effect due to the
formation of multimers from two Sp1 molecules bound
to the DNA as well as the protein-protein interaction of
Sp1 molecules [45]. Sp1 and Sp3 also contain an inhibi-
tory domain located at the N-terminus and the
C-terminus [46].
Sp1 and other transcription factors of this family are
primarily marked by their bipolar behavior [33]. Their
function as an activator or repressor of transcription
probably depends on the respective promotor or the re-
spective transcription partner [47]. The domain respon-
sible for this property is still unclear. Literature reports
have described interaction with binding partners of the
zinc fingers domains as well as the activating domains of
the N-terminus of Sp1 [42]. Lee et al. hypothesized that
the zinc finger domains of Sp1 are responsible for the
interaction with other regulatory proteins because of
their highly conservative amino acid sequence, which is
assumed to act as a positive and negative regulator in
the regulation of Sp1-DNA binding [45]. As shown in
the structural analysis, the DNA-binding domains of
Sp1, Sp3, and Sp4 are highly homologous in contrast to
Sp2 [48]. Thus, it is not surprising that Sp1, Sp3, and
Sp4 are able to bind to the classic Sp1-binding site of
the GC box in the same way. Sp2, however, binds to a
GT-rich element within the T-cell antigen receptor be-
cause of the change of amino acids from histidine to leu-
cine at the first zinc finger [14]. Despite the pronounced
homology between Sp1, Sp3, and Sp4, Sp1 has the high-
est activation potential. In contrast, Sp4 has less activa-
tion potential than Sp1, and Sp3 often has a suppressing
effect on transcription [49]. On the other hand, the
repressing functions of Sp1 and Sp3 are attributed to the
inhibiting domains at the N-terminus but not in the zinc
finger region [45].
The current study shows the interaction between the
transcription factor NFATc2 and the N-terminal domain
of Sp1 in pancreatic cancer cells. The functional rele-
vance was shown by means of luciferase assays. Sp1 in-
creases activity of NFATc2 at the NFAT-responsive
promoter. One possible explanation may be the activat-
ing serine-threonine-rich and glutamine-rich domains of
Sp1 that increase the transcription and function of
NFATc2 in pancreatic cancer.
Conclusions
The regulation of promotors in the context of transcrip-
tion is a very complex process because of the involve-
ment of several proteins that – as transcription factors
or co-factors – regulate promotor activity as required
and control cell function. In this respect, NFATc2 and
Sp1 seem to play a key role in the progression of pancre-
atic cancer. The regulating binding partners interact
within the cells and have a carcinogenic effect via tran-
scriptional modification. Inhibitors that selectively in-
hibit the activity of this interaction may represent a
novel approach to developing new therapeutic options
for this aggressive type of tumor. Further studies are re-
quired to identify underlying mechanisms and examine
their clinical importance in treating pancreatic cancer.
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